DENVER — Intravitreal anti-VEGF injections significantly decrease aqueous VEGF levels in patients with diabetic retinopathy, according to a presenter here.
“VEGF is usually the main target for diabetic retinopathy,” Bharani K. Mynampati, PhD, told Healio/OSN at the Association for Research in Vision and Ophthalmology meeting. “The therapeutic approach for diabetic retinopathy is anti-VEGF treatment.”
Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had sequential anti-VEGF injections of 1.25 mg per 0.05 mL of